Trump administration shakes up pharma industry with 'Buy American' plan

Reining in the high cost of prescription drugs has been a major aim of the Trump administration, marked most notably by the president's 2018 "Blueprint…

By Emily Payne | August 07, 2020 at 11:37 AM

Drug prices Drug manufacturers and other trade industry experts have warned that the new proposal could actually raise drug prices. (Photo: Shutterstock)

Reining in the high cost of prescription drugs has been a major aim of the Trump administration, marked most notably by the president's 2018 "Blueprint to Lower Drug Prices" directive. Since then, the administration has rolled out numerous orders and regulations aimed at bringing reform to the pharmaceutical industry–only to be met with resistance at nearly every turn.

Though many of those initiatives have been slow to get started or stalled by legal challenges, a new executive order from President Trump requiring the government to buy certain drugs from American factories could have some teeth. As reported by Stat News, as much as 90% of the country's supply of generic drugs is manufactured abroad.

Recommended For You

The order, signed Thursday, instructs the FDA to implement the new directive but allows certain drugs to be exempted if making them on U.S. soil proves cost-prohibitive. In addition, the order directs HHS to speed up FDA approval for U.S. drugs and prioritizes government contracts with domestic drug manufacturers.

Drug manufacturers and other trade industry experts have warned that the new proposal could actually raise drug prices, though White House trade advisor Peter Navarro was quick to point out the benefits of having more control over the drug supply chain.

"If we learned anything from the [coronavirus] pandemic, it is simply that we are dangerously overdependent on foreign nations for our essential medicines, for medical supplies — like masks, gloves, goggles and the like — and medical equipment, like ventilators," he said.

NOT FOR REPRINT

© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.

Emily Payne

Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.

By Allison Bell | June 30, 2025

The high court considered the Oklahoma case for more than year but then dismissed it without comment.

Supreme Court backs away from PBM case, rejecting state efforts to control drug prices in self-funded plans

By Renuka Rayasam and Sam Whitehead | June 30, 2025

Health policy researchers expect the number of uninsured to swell as the second Trump administration and a GOP-controlled Congress try to enact policies that explicitly roll back health coverage for the first time since the advent of the modern U.S. health system in the early 20th century.

Americans face catastrophic costs as Congress plans uninsured surge

By Allison Bell | June 30, 2025

Peter Nelson, the head of Trump's ACA programs, reported that some call him "Mr. ICHRA."

Self-funding, Mark Cuban and ICHRAs generate buzz at NABIP's annual convention
2025 Broker ICHRA Survey Report link

Research Report

Sponsored by Zorro and Ambetter Health

What do brokers really think about ICHRA five years in? This report reveals how the model is evolving, what’s driving adoption, and what brokers need to succeed as demand grows.

4 Key Win-Wins of Executive Medical Plans: Unlocking Far-Reaching Organizational Value link

Infographic

Sponsored by ArmadaCare

This infographic explores a cost-effective and compliant way to solve clients’ business problems before busy season hits full stride.

Advising on Annuities: The In-Plan Advantage for Your Clients link

Article

Sponsored by TIAA

Secure income is a top priority for your clients’ retirement plans, but annuities can be complex. This guide clarifies in-plan vs. retail options, empowering you to offer superior advice, highlight cost savings, and enhance client trust.